Predictive Oncology Equity 2024

Predictive Oncology Aktienanalyse

What does Predictive Oncology do?

Predictive Oncology Inc is an emerging company in the field of cancer research and treatment. It was founded in 2002 under the name Precision Therapeutics and has since focused on developing new diagnostic and therapeutic procedures for cancer. The business model of Predictive Oncology is based on collaboration with pharmaceutical companies and research institutions to develop new technologies and products for cancer therapy. The focus is on personalized medicine, which enables treatment options tailored to individual patient needs. The company is divided into several divisions, each covering different areas of cancer research. These include predictive medicine, pharmacy, and diagnostics. Predictive Oncology has developed several products that can be used in predictive medicine. This includes the OncoTect iOCT System, which allows prediction of the effectiveness of chemotherapy for a specific type of cancer. Based on genetic analysis, the system can determine before treatment whether the drug used for chemotherapy is actually effective or if another drug may be more suitable. Another important product of Predictive Oncology is the Skyline Ventures Test Kit, which is used in pharmacy. The kit allows pharmaceutical companies to test the potential effect of a new drug on specific cancer cells before testing it on patients in clinical trials. By pre-testing the effectiveness, unnecessary studies can be avoided and the development of new drugs can be accelerated. In the field of diagnostics, Predictive Oncology has developed the Cchek system, which enables early detection of certain types of cancer through RNA analysis. The system can provide indications of the development of a tumor at an early stage, enabling early treatment. One of the recent developments of Predictive Oncology is the acquisition of Soluble Therapeutics Inc, which specializes in protein analysis. Through the acquisition, Predictive Oncology hopes to further increase its capacities in personalized cancer treatment. Overall, Predictive Oncology is one of the leading companies in the field of cancer research. Through a consistent focus on personalized medicine and close collaboration with research institutions and pharmaceutical companies, the company has already produced some promising developments. In the future, it is expected that Predictive Oncology will bring further innovative products and technologies to the market to treat cancer patients more effectively. Predictive Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Predictive Oncology's Equity

Predictive Oncology's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Predictive Oncology's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Predictive Oncology's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Predictive Oncology's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Predictive Oncology’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Predictive Oncology Stock

What is the equity of Predictive Oncology this year?

Predictive Oncology has equity of 8.27 M USD this year.

What was the equity of Predictive Oncology compared to the previous year?

The equity of Predictive Oncology has increased/decreased by -62% decreased compared to the previous year.

What impact does a high equity have on investors of Predictive Oncology?

A high equity is advantageous for investors of Predictive Oncology as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Predictive Oncology?

A low equity can be a risk for investors of Predictive Oncology, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Predictive Oncology affect the company?

An increase in equity of Predictive Oncology can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Predictive Oncology affect the company?

A reduction in equity of Predictive Oncology can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Predictive Oncology?

Some factors that can affect the equity of Predictive Oncology include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Predictive Oncology so important for investors?

The equity of Predictive Oncology is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Predictive Oncology take to change the equity?

To change equity, Predictive Oncology can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Predictive Oncology pay?

Over the past 12 months, Predictive Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Predictive Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Predictive Oncology?

The current dividend yield of Predictive Oncology is .

When does Predictive Oncology pay dividends?

Predictive Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Predictive Oncology?

Predictive Oncology paid dividends every year for the past 0 years.

What is the dividend of Predictive Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Predictive Oncology located?

Predictive Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Predictive Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Predictive Oncology from 6/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.

When did Predictive Oncology pay the last dividend?

The last dividend was paid out on 6/28/2024.

What was the dividend of Predictive Oncology in the year 2023?

In the year 2023, Predictive Oncology distributed 0 USD as dividends.

In which currency does Predictive Oncology pay out the dividend?

The dividends of Predictive Oncology are distributed in USD.